4142:TPE
Adimmune Corp
16,25 TWD
arrow_downward
−0,61%(−0,10) 1 D
17. nov., 13:30:05 GMT+8 · TWD
search
Alle symboler
| Symbol | Pris | Endring | Endring (%) |
|---|
insights_autoGenererer viktig statistikk for 4142 …
Åpne
16,40 TWD
Høy
16,50 TWD
Lav
16,10 TWD
Markedsverdi
6,98 mrd.
Snittvolum
1,09 mill.
Volum
629,98k
52 u høy
22,50 TWD
52 u lav
15,65 TWD
EPS
−0,34 TWD
Utestående aksjer
235,29 mill.
Antall ansatte
564
Åpne
16,40 TWD
Høy
16,50 TWD
Lav
16,10 TWD
Markedsverdi
6,98 mrd.
Snittvolum
1,09 mill.
Volum
629,98k
52 u høy
22,50 TWD
52 u lav
15,65 TWD
EPS
−0,34 TWD
Utestående aksjer
235,29 mill.
Antall ansatte
564
Nyhetssaker
Fra nettkilder og nyhetspartnere
TradingView
·
for 1 time siden
Stock Market Today: Dow Jones, S&P 500, Nasdaq 100 Futures Trade Mixed Ahead of Nvidia’s Q3 Earnings— CBRS, AMZN, RCAT in Focus (UPDATED)
The Motley Fool
·
for 1 time siden
Prediction: Dec. 9 Will Mark a Turning Point for the S&P 500
Coinpaper
·
for 29 minutter siden
Stock Market Today: S&P 500 Struggles Ahead of Nvidia Earnings After $2 Trillion Stock Rout
The Defiant
·
for 14 timer siden
Ondo Launches S&P 500 Portfolio Token With Loss Buffers
Profil
Adimmune Corporation is a Taiwanese pharmaceutical company engaged in the research, development, manufacturing, and sales of medicines and vaccines for both humans and animals. Its products are supplied to both local and international markets.
Founded in 1965 and headquartered in Tanzi District, Taichung, it has a market cap of US$230 million, 564 employees and annual sales of $106 million as of 2026.
Adimmune continues to seek expansion its role in the regional pharmaceutical and vaccine industry through international collaborations.
In January 2021, Adimmune Corporation announced a partnership with Sam Chun Dang Pharm to jointly develop an injectable medication used to treat macular disease.
In July 2021, the company announced that its first overseas manufacturing site will be situated in the Special Economic Zone in East Java, Indonesia, aiming to launch clinical trials for its COVID-19 vaccine in Indonesia early 2022.
In August 2021, Adimmune Corporation signed a memorandum of understanding with Becton, Dickinson and Company to strengthen its international pharmaceutical collaboration. Wikipedia
Om Adimmune Corp
Administrerende direktør-
Ansatte564
Grunnlagt1965
Hovedkontor-
SektorHealth Care
Bransje-
Nettstedadimmune.com.tw